Core Viewpoint - Aimfinity Investment Corp. I (AIMA) has successfully approved its business combination with Docter Inc., a Taiwanese health technology company, with approximately 93.8% of votes in favor at the extraordinary general meeting of shareholders [1] Group 1: Business Combination Details - The business combination between AIMA and Docter was approved on March 27, 2025, at an extraordinary general meeting [1] - AIMA has extended the deadline for completing the business combination from March 28, 2025, to April 28, 2025, by depositing 0.05 per Class A ordinary share held by public shareholders [2] - AIMA's current charter allows for monthly extensions of the business combination deadline until October 28, 2025, with this being the third of nine available extensions [3] Group 2: Company Profiles - Aimfinity Investment Corp. I is a special purpose acquisition company (SPAC) focused on merging with high-growth potential businesses to facilitate their entry into capital markets [4] - Docter Inc. is a leading health technology company that develops innovative health monitoring solutions aimed at enhancing the accessibility and efficiency of global healthcare services [5] Group 3: Regulatory and Procedural Information - AIMA entered into a merger agreement with Docter on October 13, 2023, which involves a reincorporation merger and an acquisition merger [6] - AIMA has filed a final prospectus with the SEC on March 6, 2025, detailing the proposed transactions, and proxy materials have been mailed to shareholders [11]
Aimfinity Investment Corp. I Announces Approval by Shareholders of its Business Combination with Docter Inc.